NCT03032614

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.

Detailed description

This is a Phase II, non-randomized, open-label, Clinical Trial on the Combination of Carboplatin, Eribulin, and Veliparib in Patients with BRCA-related Cancers.

Conditions

• Breast Cancer Stage IV
• Ovarian Cancer
• BRCA1 Mutation
• BRCA2 Mutation

Interventions

Type	Name	Description
DRUG	Carboplatin	Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
DRUG	Eribulin	Eribulin Mesylate is a synthetic halichondrin analog.
DRUG	Veliparib	Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.

Timeline

• Start date: 2017-09-30
• Primary completion: 2019-03-31
• Completion: 2020-04-30
• First posted: 2017-01-26
• Last updated: 2017-10-10

Regulatory

• FDA-regulated drug study